Scientists at IMBA - Institute of Molecular Biotechnology at the Austrian Academy of Sciences - together with the Boston Children's Hospital at Harvard, demonstrate a completely new way of combating autoimmune diseases and cancer.

Apply by 15th November 2018.

This year´s PhD symposium takes place on November 8th and 9th 2018 broaching the issue of change in science

Stem Cell pavilion curated by IMBA director Jürgen Knoblich counted thousands of visitors at the 50th Birthday Science Festival from The Austrian Science Fund (FWF).

IMBA was once more successful in competing for an European Research Council (ERC) grant: Stefan Ameres was awarded a Proof of Concept Grant to explore the commercial potential of his newly developed technology SLAMseq. After receiving the recognized…

The city of Vienna annually awards several Funding Awards in the categories music, literature, architecture, national education, visual arts and science. These Awards are given in recognition of excellent overall achievements in one of the fields and…

For the first-time, researchers at IMBA- Institute of Molecular Biotechnology of the Austrian Academy of Sciences – develop organoids, that mimic the onset of brain cancer. This method not only sheds light on the complex biology of human brain tumors…

On 15 July, Josef Penninger officially stepped down from his position as Scientific Director at IMBA. Having been at the helm for more than 15 years and as its founding director, he helped to develop IMBA into the largest institute of the Austrian…

Keystone Symposia in collaboration with Vienna BioCenter is pleased to announce the inaugural Keystone Symposia scientific conference in Vienna, to be held November 11-14, 2018 on the topic of “Rare to Care: Discovery, Modeling and Translation of…

APEIRON strengthens its proprietary Cbl-b portfolio with cutting edge immunotherapy technology developed at IMBA.